ライフサイエンスコーパス: graft

1 n lasted only for the duration of the uterus graft.

2 ellitus) were randomized to receive RA or SV graft.

3 ikely to transition to either a fistula or a graft.

4 inflammatory status of the host, and type of graft.

5 ction using a temporary split-thickness skin graft.

6 MELD patients transplanted with "high-risk" grafts.

7 bm1 or F1) and third-party B10.BR (H-2) skin grafts.

8 or third-party (C3H, H2K(k), I-A(k)) cardiac grafts.

9 he grafts that promoted cell survival in the grafts.

10 ed with autografts, allografts and synthetic grafts.

11 patients (two in each study group) had skin grafts.

12 as NRP and HOPE may offer safer use of cDCD grafts.

13 attained in 60% of treated mice bearing 4T07 grafts.

14 rm died with functioning pancreas and kidney grafts.

15 tracycline (TCN) on the repair of onlay bone grafts.

16 ation led to permanent acceptance of F1 skin grafts.

17 ise elicited focal synaptic responses within grafts.

18 Electrochemically grafted 4-ABA not only leads to a favorable orientation

19 y modified MMTV-PyMT mice and orthotopically grafted 4T1 tumor cells.

20 t elective colectomy, coronary artery bypass grafting, abdominal aortic aneurysm repair, abdominal ao

21 atelet-rich fibrin (L-PRF) + autogenous bone graft (ABG) may be a clinically "non-inferior" treatment

22 Use of well-selected right lobe grafts (adequate future liver remnant in donor, GRWR in

23 s that can lead to complete occlusion of the graft, affecting long-term clinical outcomes.

24 of old recipients (18 months) had lost their graft after 100 days.

25 uantify glycocalyx damage within human liver grafts after organ preservation and correlate the result

26 facilitating robust microvasculature in lung grafts after transplantation, leading to better posttran

27 n independent positive predictive factor for graft and patient survival (hazard ratio [HR]: 0.67; P =

28 Graft and patient survival among HIV-infected LT recipie

29 ociations between County Health Rankings and graft and patient survival post-LT.

30 One-year tumor-death censored graft and patient survival was 93% versus 86% (P = 0.125

31 raft and patient survival, and predictors of graft and patient survival were assessed.

32 a, postoperative outcomes and complications, graft and patient survival, and predictors of graft and

33 Early and Normal patients had similar graft and patient survival.

34 NMP maintains excellent graft and patient survival.

35 ary endpoint was 1-year tumor-death censored graft and patient survival.

36 define the role of pMRI in predicting kidney graft and patient's survival.

37 ere existed limited studies on interspecific grafting and approaches.

38 re likely to prescribe antibiotics with bone grafting and as complexity of the bone grafting procedur

39 by complementarity-determining region (CDR) grafting and framework fine tuning and again co-crystall

40 ent approaches include the use of biological grafts and alternative engineering approaches have made

41 Hemodynamics were clinically similar between grafts and control aortic roots.

42 ted engineered MSCs were undetectable within grafts and lacked anchoring fibril reconstitution.

43 ion reactions to ABO-incompatible allogeneic grafts and xenogeneic grafts from other species.

44 variates (race/ethnicity, malignant disease, graft, and graft-versus-host-disease prophylaxis), ST2 r

45 s Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT01121224) prospective, double-blin

46 For full-thickness corneal grafts, antifungal supplementation was less cost-effecti

47 he grafted sites were studied in two of four grafting approaches in the first and the second year dur

48 Evaluations of the grafting approaches were made by comparing survival and

49 Graft assessment was performed using NMP via double perf

50 of these, 39 patients still had a functional graft at last follow up and 9 (18.8%) pancreas grafts we

51 icantly better than therapeutic and tectonic grafts at all time points.

52 used rhizoboxes, X-ray computed tomography, grafting, auxin transport measurements and hormone quant

53 include reduced patient morbidity, unlimited graft availability, and comparable esthetics.

54 ng implant placement in grafted (GG) and non-grafted bone (NGG).

55 statistically significant in the density of grafted bone was found with the addition of steroids (P-

56 HCR and conventional coronary artery bypass graft (CABG) surgery medium-term outcomes.

57 Neural stem/progenitor cell (NSPC) grafts can integrate into sites of spinal cord injury (S

58 enomena were derived from alterations in the grafted cardiomyocyte characteristics.

59 o yields could be consistently achieved with grafted combination (HM/MU and HM/ES) especially under h

60 n for donation after circulatory death renal grafts compared with conventional hypothermic methods.

61 aphics, donor cornea source, indications for grafting, complications, graft survival rate, and causes

62 Seedling grafting could provide additional crop improvement strat

63 of guidelines for procedures involving bone grafts creates additional difficulty in decision making

64 erm results 20 years after connective tissue grafting (CTG) or guided tissue regeneration (GTR) using

65 was found to proceed rapidly leading to high grafting densities, while o-methylbenzaldehyde functiona

66 n microscopy demonstrates myelination of the graft-derived axons in the corpus callosum and that thei

67 ized immunosuppression and potentially delay graft destruction in future human islet transplantation

68 Stent graft devices for the treatment of abdominal aortic aneu

69 Graft dimensional measurements were taken at time of sur

70 Vein graft disease (VGD) and failure result from complex path

71 poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol) (mPEG-b-PCC-g-DC) polymeric nanoparticl

72 ng number of an organ's demand and long-term graft dysfunction constitute some of the major problems.

73 ent endoscopy and biopsy without evidence of graft dysfunction does not appear to confer survival adv

74 Correlations of PP with graft factors, 90-day graft loss, early allograft dysfun

75 models for the primary outcomes of all-cause graft failure (ACGF) and 12-month estimated glomerular f

76 n (aOR=(1.09)1.16(1.23)), slightly increased graft failure (aHR=(1.01)1.06(1.12)), but decreased mort

77 VN was associated with an increased risk for graft failure (and functional decline in class 2 at 24 m

78 nteraction was statistically significant for graft failure (P=0.04) and mortality (P=0.003), but not

79 thelial cell count (ECC), rates of secondary graft failure (SGF), and postoperative complications.

80 dents) was associated with a similar risk of graft failure (subdistribution hazard ratio [sHR] 0.74;

81 eas grafts were lost due to patient death or graft failure after >25 years.

82 after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages.

83 the only curative option, but a high risk of graft failure and poor immune reconstitution have been o

84 rocoagulant phenotype) could predict midterm graft failure and to investigate potential functional ro

85 HOUSES) would serve as a predictive tool for graft failure in patients (n = 181) who received a kidne

86 main long-term complications leading to late graft failure in penetrating keratoplasty (PK).

87 Factors that predicted death-censored graft failure independent of both donor and recipient cl

88 Primary and secondary graft failure occurred in 3 (0.3%) and 2 eyes (0.2%), re

89 The total all-cause graft failure rate at 5 years was 0.58% for DALK (2 of 3

90 sented during long-term follow-up with a low graft failure rate: 5% class 1, vs 30% class 2, vs 50% c

91 ad a slightly higher risk for posttransplant graft failure than patients traveling <=60 miles (hazard

92 ications, graft survival rate, and causes of graft failure were analyzed.

93 Three re-DMEK eyes developed graft failure, all achieving final BCVA <=0.30 logMAR (S

94 to identify the risk factors associated with graft failure.

95 echanisms, would suggest strategies to limit graft failure.

96 8(+) T cells associated with reduced risk of graft failure.

97 tage-specific milestones, as well as data on graft failure.

98 of congenital glaucoma were risk factors for graft failure.

99 munologic rejection, herpetic recurrence and graft failure.

100 limited by the lack of robust predictors of graft failure.

101 ficant retrocorneal membranes at the time of graft failure.

102 e, to gain better insight into the causes of graft failure.

103 s 6.3 years, during which 287 death-censored graft failures and 424 deaths occurred.

104 soft tissue augmentation using free gingival grafts (FGG) at implant sites over a 3-month follow-up p

105 n = 27), palatal wounds, after free gingival grafts (FGG) harvest, received sham application of elect

106 es as alternatives to autogenous soft tissue grafts for periodontal and peri-implant plastic surgical

107 ncompatible allogeneic grafts and xenogeneic grafts from other species.

108 is combined with high-throughput analysis of grafted-from polymerization kinetics, accelerating react

109 Cox regression, acute rejection, and delayed graft function (DGF) using logistic regression, and leng

110 as not significantly associated with delayed graft function (OR, 1.16; 95% CI, 0.94-1.43; P = 0.16),

111 acrovesicular steatosis, does not compromise graft function and outcomes and is safe for the donor.

112 nd 12-month treatment failure rates, delayed graft function and renal function, and patient and graft

113 iod preceding the IL-10 response, but stable graft function following the response.

114 results with graft injury and postoperative graft function in patients undergoing orthotopic liver t

115 Graft function remained stable with a mean estimated glo

116 was no effect of arteriosclerosis on delayed graft function, estimated glomerular filtration rate at

117 te rejection, graft loss, or death), delayed graft function, patient and graft survival rates, and re

118 r filtration rate, and occurrence of delayed graft function.

119 response was associated with relatively low graft function.

120 inson's disease (PD) models, whether and how grafts functionally repair damaged neural circuitry in t

121 ollow-up cohort study included 263 KTRs with grafts functioning at least 1 year after transplantation

122 ling outcomes following implant placement in grafted (GG) and non-grafted bone (NGG).

123 to the electrostatic repulsion between 4-ABA-grafted graphene layers.

124 Only SG and Uni-Graft groups experienced relative cusp closing forces ap

125 ication, Stanford modification, and Valsalva graft groups.

126 Colon inclusive grafts had higher complication rates (P = 0.002).

127 The histomorphometric analyses revealed that grafts harvested with TDT exhibited a significantly high

128 Connective tissue grafting has a beneficial effect on the peri-implant muc

129 -0.79]; P<0.0001) and coronary artery bypass grafting (hazard ratio, 0.61 [95% CI, 0.45-0.81]; P=0.00

130 a fistula but more likely to transition to a graft, Hispanics were significantly more likely to trans

131 Angio-CT followed by stent-graft implantation over a short time interval (within th

132 fe and effective as AADI placed with a patch graft in pediatric and adult refractory glaucomas.

133 utilized closure devices alone in 61%, stent grafts in 17%, balloon tamponade facilitated closure in

134 glish language literature on the use of BADM grafts in eyelid reconstruction.

135 accelerated the rejection of allogeneic skin grafts in young RAG2(-/-) recipient mice.

136 breakthrough of B cells and their aggressive graft infiltration.

137 ed with histological evidence of more severe graft inflammation and fibrosis.

138 preservation and correlate the results with graft injury and postoperative graft function in patient

139 istopathological phenotype(s) of subclinical graft injury.

140 AADI placed without a scleral patch graft is as safe and effective as AADI placed with a pat

141 luence of the polymer nanostructure (thin or grafted layers, polymer ordering, polymer nanopores), ar

142 after adjustment for time-varying covariate graft loss (aHR, 1.68 [1.08-2.62]; P = 0.022) and biopsy

143 sociated with a 0.9% increase in the risk of graft loss (hazard ratio [HR], 1.009; P < 0.001).

144 411.70; P < 0.001) and 39% increased risk of graft loss (HR: 1.161.391.66; P < 0.001) with steatotic

145 The increased risk of 1-y graft loss among en bloc recipients only appeared in the

146 mpaired renal function have a higher risk of graft loss and death.

147 Graft loss at 1 month and 1 year was similar between gro

148 ed glomerular filtration rate < 30 mL/min or graft loss at 1 y, n = 66) were analyzed by using a mult

149 transplantation (LT) that is associated with graft loss at 3 months after LT.

150 was observed only in HCV patients with first graft loss due to disease recurrence (HR: 0.31; P = .002

151 Finally, gDSA predicted subsequent graft loss in patients who showed a stable renal functio

152 Graft loss or death occurred in about one third of recip

153 Ratios for mortality and graft loss were similar between VA centers and their res

154 Only 1 episode was associated with graft loss, but this was in the context of a mixed rejec

155 orrelations of PP with graft factors, 90-day graft loss, early allograft dysfunction (EAD), L-GrAFT s

156 ment failure (biopsy-proven acute rejection, graft loss, or death), delayed graft function, patient a

157 (aHR, 1.83; P < 0.001) were associated with graft loss, whereas more recent period of LT 2012-2015 (

158 ated with an increased risk of mortality and graft loss.

159 infection and rejection are major causes of graft loss.

160 = 0.007) were associated with lower risk of graft loss.

161 was a composite of estimated GFR halving and graft loss.

162 alently immobilized onto polyethylene glycol grafted magnetic nanoparticles via trichlorotriazine wit

163 Tissue-engineered grafts may be useful in Anterior Cruciate Ligament (ACL)

164 esponding catalysts synthesized by different grafting methods.

165 .58) and lowest after coronary artery bypass grafting + mitral valve surgery (1.38; 95% CI, 1.11-1.70

166 All the steps leading to the final grafted molecular complex have been identified by DFT.

167 biomechanical performance, with the straight graft most closely recapitulating native aortic root bio

168 bullous keratopathy [BK]: n = 24; and failed graft: n = 18).

169 For transplantation to be effective, grafted neurons should migrate to affected areas at a fa

170 estigate potential functional role of MVs in graft occlusion.

171 quentially modified by EDC-NHS crosslinkers, grafting of protein-A and finally interaction with anti-

172 Grafting of the Asn(81)-Asn(149) fragment within the pri

173 ed in the improvement of fruit traits by the grafting of watermelon and bottle gourd.

174 ve of Pd(16) with a tetra-palladium-oxo unit grafted on either side.

175 pite several field studies on the effects of grafting on fruit quality, the regulation of this proces

176 imine photocyclization has been explored for grafting on the bay region of perylenediimide (PDI) diff

177 est after light-induced inhibition of either grafted or endogenous halorhodopsin-expressing cortical

178 NSPC grafts organize into localized and spontaneously active

179 demonstration of low incidence of poor early graft outcomes and the presence of a "safety net" would

180 responses are typically associated with poor graft outcomes in experimental and clinical transplantat

181 Extensive resorption of graft particles was observed in group DBG, which was not

182 formed bone [PNFB], percentage of remaining graft particles, histochemical, and immunohistochemical

183 tic value of microvesicles (MVs) for midterm graft patency has never been tested.

184 (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Byp

185 ess MC and EC-specific proteins and maintain graft patency.

186 lation has been advocated for saphenous vein graft percutaneous coronary intervention to decrease the

187 The antioxidant effect of the tannic acid grafted polypropylene copolymers (PP-Tann) retarded olig

188 bone grafting and as complexity of the bone grafting procedure increases.

189 dy was to evaluate the impact of soft tissue grafting procedures conducted over a decade ago on the w

190 In KTA recipients, graft quality correlates directly to graft survival.

191 Adoptively transferred TEa cells in skin-graft recipients were not exhausted.

192 e (OR = 2.67; 95% CI = 1.12-6.32), and acute graft rejection (OR = 3.01; 95% CI = 1.78-5.09).

193 We further demonstrate that late graft rejection in recipients treated with this regimen

194 ccessful strategies to induce suppression of graft rejection relies on inhibition of T-cell activatio

195 Endothelial failure and immunological graft rejection remain long-term complications leading t

196 ipheral En/DMT correlated significantly with graft rejection severity (r = 0.972, r = 0.729, and r =

197 ted islets maintained euglycemia and delayed graft rejection significantly longer than those receivin

198 t, but the role of early vascular lesions in graft rejection warrants additional analysis.

199 fic antibody responses and accelerated heart graft rejection.

200 edict adjudicated non-coronary artery bypass grafting-related GUSTO (Global Use of Strategies to Open

201 The current literature suggests that BADM grafts represent an implantation option for lower eyelid

202 lemeter to record cardiovascular parameters, grafting RN-NSCs restored resting mean arterial pressure

203 t loss, early allograft dysfunction (EAD), L-GrAFT score, acute kidney injury, and comprehensive comp

204 Results suggested that grafting seedlings and allowing time to heal graft wound

205 Grafting showed that CEPR1 in the shoot controls GSA.

206 The formation of any lateral shoots at the grafted sites were studied in two of four grafting appro

207 recipient age, CC, non-DBD donor and reduced graft size.

208 n Patients Undergoing Coronary Artery Bypass Grafting Surgery) investigated whether ticagrelor added

209 recipients, en bloc recipients had lower 1-y graft survival (78.9% versus 88.9%; P = 0.007); however,

210 and 76.0%; P = .3), death-censored pancreas graft survival (CACPR: 89.3%, 82.7%, 75.0%; non-CACPR: 8

211 %, 76.3%; P = .7), and death-censored kidney graft survival (CACPR: 97.0%, 89.5%, 78.2%; non-CACPR: 9

212 ear patient survival (PS) and death-censored graft survival (DCGS) based on 6662 patients in the Thai

213 CI, -2.07 to 3.22; P = 0.67), and long-term graft survival (hazard ratio, 1.07; 95% CI, 0.86-1.33; P

214 were organ utilization rate and patient and graft survival after 1 year.

215 tocols based on these findings could improve graft survival after SL transplantation, which would enc

216 e of rapamycin regimen resulted in sustained graft survival and function in >90% of allogeneic recipi

217 Short-term graft survival and outcomes of primary transplants for F

218 Primary outcomes included graft survival and rejection rates, and secondary outcom

219 Patient and graft survival at 3 years posttransplantation were 74% (

220 Pancreas graft survival at 52 weeks, defined by insulin independe

221 onths, there was no difference in patient or graft survival between the EW and non-EW cohorts.

222 Graft survival for optical grafts was significantly bett

223 irm the nonsignificant trend towards a lower graft survival in CMV high-risk patients treated with be

224 Three-year cumulative graft survival in LT recipients with and without HIV inf

225 The mechanism for similar graft survival is unclear.

226 Graft survival measured 87% at 3 months, 85% at 6 months

227 Ten-year graft survival outcomes were compared.

228 ce, indications for grafting, complications, graft survival rate, and causes of graft failure were an

229 death), delayed graft function, patient and graft survival rates, and renal function.

230 By extending graft survival to 3 months, the ASM will optimize eye ba

231 We compared mortality and death-censored graft survival using Cox regression, acute rejection, an

232 Graft survival was also poorer in those who had been sus

233 Graft survival was significantly superior for patients r

234 function and renal function, and patient and graft survival were not different between the arms.

235 Patient and graft survival were studied using Kaplan-Meier method, l

236 athy occurred the earliest and had the worst graft survival, AL amyloidosis occurred the latest and h

237 th early allograft dysfunction (EAD), 1-year graft survival, and 1-year patient survival.

238 Graft survival, patient survival, and complications were

239 eceased donors being associated with reduced graft survival, recipients had lower mortality rates tha

240 pients, graft quality correlates directly to graft survival.

241 Multivariable Cox models were used to assess graft survival.

242 era was associated with improved patient and graft survival.

243 kade in BD donors to prevent DGF and improve graft survival.

244 t the time of transplantation prolonged skin graft survival.

245 merular filtration rate at 1 y, or long-term graft survival.

246 The principal outcome was patient and graft survival.

247 g Tac IPV are crucial to improving long-term graft survival.

248 combined with low-dose rapamycin to prolong graft survival.

249 oidosis occurred the latest and had the best graft survival.

250 fer of these three MDSCs led to differential graft survival: control (6 days), tx-MDSCs (7.5 days), t

251 , we developed a polymeric-based constructed graft system (CGS) as a physiologically relevant model t

252 functional human-mouse blood vessels in the grafts that promoted cell survival in the grafts.

253 n the peri-implant mucosa, but the effect of grafting the buccal mucosa on buccal bone thickness (BBT

254 In the multivariable model, grafting the second ITA to multiple important targets wa

255 In patients receiving LD grafts, the expression of most genes did not remain mark

256 osed to replace autogenous connective tissue grafts, therefore the aims of this study are to report c

257 Grafting those UB-like structures into peri-Wolffian mes

258 saccharides, and oligopeptides, prepared via graft-through polymerization from biomolecule functional

259 g of various molecular mechanisms underlying grafted tissues in watermelon.

260 A saphenous vein graft to an important or less important target did not i

261 atients with a nondominant LAD, a second ITA grafted to a less important artery was associated with h

262 rved in LTRs withdrawn from SRL and if blood/graft tolerance biomarkers were predictive of successful

263 renal function before and after aortic stent-graft treatment was performed.

264 iabetes recipients of intraportal islet cell grafts under antithymocyte globulin induction and mycoph

265 One hundred thirty-five grafts underwent ileostomy formation, and 79 underwent i

266 reporting during surgery, (2) intraoperative graft unscrolling efficiency, and (3) frequency of posto

267 fforts to increase arteriovenous fistula and graft use, 80% of patients in the United States start he

268 Here we construct autologous jejunal mucosal grafts using biomaterials from pediatric patients and sh

269 models, including organ transplantation and graft versus host disease (GVHD) but they have limitatio

270 Acute graft-versus-host disease (GVHD) is initially triggered

271 Despite graft-versus-host disease (GVHD) prophylactic agents, th

272 While tacrolimus and sirolimus (T/S)-based graft-versus-host disease (GvHD) prophylaxis has been ef

273 Graft-versus-host disease (GVHD) remains an important ca

274 Graft-versus-host disease (GVHD), a common complication

275 relapse mortality, and severe (grade 3 or 4) graft-versus-host disease (GVHD), all evaluated through

276 Graft-versus-host disease (GVHD), however, remains one o

277 y as observed in a mouse model of intestinal graft-versus-host disease (GVHD), providing a roadmap fo

278 gressive immunosuppression to better control graft-versus-host disease (GvHD).

279 nal microbiome-dependent metabolite, worsens graft-versus-host disease (GVHD).

280 teroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the mo

281 eneic CAR T cells may cause life-threatening graft-versus-host disease and may be rapidly eliminated

282 oth patients were alive, without evidence of graft-versus-host disease, with major infection at 1 yea

283 ASIX) was shown to predict death after acute graft-versus-host disease.

284 ace/ethnicity, malignant disease, graft, and graft-versus-host-disease prophylaxis), ST2 remained ass

285 t eliminating A20-luciferase B-cell lymphoma graft-versus-leukemia (GVL).

286 atal donor sites following connective tissue grafting via the SIT.

287 a promising treatment for T1D, but long-term graft viability and function remain challenging.

288 Liver graft viability assessment has long been considered a li

289 APF with any evaluated soft tissue graft was associated with with reduction of probing dept

290 Graft survival for optical grafts was significantly better than therapeutic and tec

291 Right lobe graft weight (764.8 + 145.46 vs 703.24 + 125.53 grams; P

292 aft at last follow up and 9 (18.8%) pancreas grafts were lost due to patient death or graft failure a

293 A total of 132 and 93 liver grafts were transplanted after NRP and HOPE, respectivel

294 l biopsies, in the form of connective tissue grafts, were obtained from periodontally healthy smokers

295 A peritoneal pouch graft with high tissue volume (1000 islets) could be vis

296 acrylic stent, and the extraction socket was grafted with the combination allograft and covered with

297 Grafts with >=30% MaS exhibited significantly different

298 Transplantation of SA-PDL1-engineered islet grafts with a short course of rapamycin regimen resulted

299 Grafts with all cells cultured >=96 hours did not contai

300 grafting seedlings and allowing time to heal graft wounds prior to spring transplanting or double cro